UroGen Pharma Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
UroGen Pharma Ltd. (URGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 122.50 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-02
- UroGen Pharma Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 122.50K shares.
- UroGen Pharma Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 530.00K shares, a 29.25% increase from fiscal 2022.
- UroGen Pharma Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 410.06K shares, a 30.85% decline from fiscal 2021.
- UroGen Pharma Ltd. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 593.00K shares, a 48.03% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|
| 2025-12-31 | 122.50K shares 10-K · filed 2026-03-02 | |
| 2024-12-31 | 238.61K shares 10-K · filed 2025-03-10 | |
| 2023-12-31 | 530.00K shares 10-K · filed 2024-03-14 | |
| 2022-12-31 | 410.06K shares 10-K · filed 2024-03-14 | |
| 2021-12-31 | 593.00K shares 10-K · filed 2023-03-24 | |
| 2020-12-31 | 400.60K shares 10-K · filed 2022-03-21 | |
| 2019-12-31 | 955.73K shares 10-K · filed 2021-03-18 | |
| 2018-12-31 | 1.20M shares 10-K · filed 2020-03-02 | |
| 2017-12-31 | 589.60K shares 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |